Wout Devlies

Dr. Wout Devlies

KU Leuven
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAntti Kiviaho
Antti Kiviaho
SESini K. Eerola
Sini K. Eerola
HKHeini M. L. Kallio
Heini M. L. Kallio
MAMaria Karoline Andersen
Maria Karoline Andersen
MHMiina Hoikka
Miina Hoikka
MNMatti Nykter
Matti Nykter
Prostate cancer treatment resistance is a significant challenge facing the field. Genomic and transcriptomic profiling have partially elucidated the mechanisms through which cancer cells escape treatment, but their relation toward the tumor microenvironment (TME) remains elusive. Here we present a comprehensive transcriptomic landscape of the prostate TME at multiple points in the standard treatment timeline employing single-cell RNA-sequencing and spatial transcriptomics data from 120 patients. We identify club-like cells as a key epithelial cell subtype that acts as an interface between the prostate and the immune system. Tissue areas enriched with club-like cells have depleted androgen signaling and upregulated expression of luminal progenitor cell markers. Club-like cells display a senescence-associated secretory phenotype and their presence is linked to increased polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) activity. Our results indicate that club-like cells are associated with myeloid inflammation previously linked to androgen deprivation therapy resistance, providing a rationale for their therapeutic targeting.

15 September 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
GDGaëtan Devos
Gaëtan Devos
Wout DevliesWout Devlies
Wout Devlies
GMGert De Meerleer
Gert De Meerleer
MBMarcella Baldewijns
Marcella Baldewijns
TGThomas Gevaert
Thomas Gevaert
Steven JoniauSteven Joniau
Steven Joniau

1 January 2021 in European Urology
Verified
Journal Article
Closed access
APAdrian Pilatz
Adrian Pilatz
RVRajan Veeratterapillay
Rajan Veeratterapillay
KDKonstantinos Dimitropoulos
Konstantinos Dimitropoulos
MOMuhammad Imran Omar
Muhammad Imran Omar
Benjamin PradereBenjamin Pradere
Benjamin Pradere
GBGernot Bonkat
Gernot Bonkat

18 October 2021 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
SKSarah El Kharraz
Sarah El Kharraz
VDVanessa Dubois
Vanessa Dubois
MRMartin Van Royen
Martin Van Royen
AHAdriaan B. Houtsmuller
Adriaan B. Houtsmuller
EPEkaterina Pavlova
Ekaterina Pavlova
FCFrank Claessens
Frank Claessens

6 February 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SPSamuel P. Pitzen
Samuel P. Pitzen
ARAmber N. Rudenick
Amber N. Rudenick
YQYinjie Qiu
Yinjie Qiu
WZWeijie Zhang
Weijie Zhang
SMSarah A. Munro
Sarah A. Munro
Scott DehmScott Dehm
Scott Dehm
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal epithelial cell identity. Tumors progress during therapy to castration-resistant prostate cancer (CRPC) by restoring AR signaling and maintaining luminal identity or by converting through lineage plasticity to a neuroendocrine (NE) identity or double-negative CRPC (DNPC) lacking luminal or NE identities. Here, we show that DNPC cells express genes defining basal, club, and hillock epithelial cells from benign prostate. We identified KLF5 as a regulator of genes defining this mixed basal, club, and hillock cell identity in DNPC models. KLF5-mediated upregulation of RARG uncovered a DNPC sensitivity to growth inhibition by retinoic acid receptor agonists, which down-regulated KLF5 and up-regulated AR. These findings offer CRPC classifications based on prostate epithelial cell identities and nominate KLF5 and RARG as therapeutic targets for CRPC displaying a mixed basal, club, and hillock identity.

22 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Wout DevliesWout Devlies
Wout Devlies
FHFlorian Handle
Florian Handle
GDGaëtan Devos
Gaëtan Devos
Steven JoniauSteven Joniau
Steven Joniau
FCFrank Claessens
Frank Claessens
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.